Breaking News, Collaborations & Alliances

Daiichi and GENESIS Will Commercialize VANFLYTA in Parts of Europe

An exclusive license and supply agreement covers 13 Central and Eastern European markets.

Author Image

By: Patrick Lavery

Content Marketing Editor

Daiichi Sankyo and GENESIS Pharma have an exclusive license and supply agreement for distribution and commercialization of quizartinib, brand name VANFLYTA. Thirteen markets in Central and Eastern Europe will be impacted. Quizartinib is indicated for treatment of adults with FMS-like tyrosine kinase 3—internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML). As branded, VANFLYTA is available in oral form. More than 30 countries and regions have advanced the treatment. D...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters